KRAS Inhibitors Market to Witness Strong Growth and Significant Market Expansion by 2034 - DelveInsight

DelveInsight's "KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the KRAS Inhibitors, historical and forecasted epidemiology as well as the KRAS Inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the KRAS Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; KRAS Inhibitors Market Forecast
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the KRAS Inhibitors Market Report:
• The KRAS inhibitors market size across the 7MM was estimated at USD 526 million in 2025 and is anticipated to grow significantly with a CAGR of 35%, reaching USD 7,847 million by 2034 over the forecast period from 2025 to 2034.
• In August 2026, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for adults with advanced pancreatic cancer who have received at least one prior systemic treatment and whose tumors carry a KRAS G12C mutation confirmed through an FDA-approved test. Olomorasib is an investigational, potent, and highly selective next-generation KRAS G12C inhibitor. The therapy had previously received Breakthrough Therapy designation in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation and PD-L1 expression of ≥50%, as determined by FDA-approved tests.
• In May 2025, Verastem Oncology announced that the U.S. FDA has granted approval for AVMAPKI + FAKZYNJA CO-PACK (avutometinib capsules and defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously received systemic therapy. This combination marks the first and only FDA-approved treatment for this condition. The approval was granted under the accelerated approval pathway, based on tumor response rate and duration of response (DoR).
• In April 2025, BMS announced anticipation of Phase III trial data readouts for KRYSTAL-10 by 2026 for 2L CRC, KRYSTAL-7 trial results in 2028 for 1L NSCLC PD-L1=50%, and KRYSTAL-4 trial results in 2029 for 1L.
• In March 2025, Verastem Oncology announced plans to launch avutometinib in the first-half of 2025 to maximize market opportunity in KRAS mutant recurrent LGSOC. The company plans to submit for National Comprehensive Cancer Network (NCCN) Guideline inclusion upon FDA approval, which may enable patients with KRAS wild-type LGSOC to access therapy.
• In January 2025, Elicio Therapeutics announced that, based on the feedback from the FDA in the End of Phase I Type B meeting, the company anticipates submitting a BLA contingent upon the results of a planned Phase III trial.
• Within the 7MM, the United States held the largest share of the KRAS inhibitors market in 2024, representing approximately 70% of the total market value.
• Among the three RAS genes, KRAS is the most commonly mutated, followed by NRAS and HRAS. Mutations in KRAS are frequently linked to various cancers, including pancreatic, colorectal, lung adenocarcinomas, ovarian, and several others.
• Among the approved therapies in the United States, KRAZATI is projected to outperform LUMAKRAS in revenue generation over the study period (2020-2034). The United States also recorded the highest number of KRAS mutation cases in NSCLC within the 7MM, accounting for approximately 46% of all such cases.
• Several KRAS inhibitor companies are concentrating on developing pan-KRAS candidates, including Cardiff Oncology (onvansertib), Immuneering Corporation (IMM-1-104), Jacobio Pharma (JAB-23E73), Eli Lilly and Company (LY4066434), among others. These therapies are anticipated to have significant market potential owing to the wide patient population they can target.
• In 2024, the total KRAS-mutated cases across the 7MM exceeded ~509,700 and are expected to rise throughout the forecast period.
• Among the analyzed cancer types, KRAS mutations are most prevalent in colorectal cancer (CRC), followed by pancreatic cancer, NSCLC, and LGSOC. In the U.S. alone, approximately ~66,000 KRAS-mutant CRC cases were reported in 2024.
• G12C is the most commonly detected KRAS mutation in NSCLC. Meanwhile, G12D is the predominant KRAS variant in colorectal cancer (CRC), pancreatic cancer, and LGSOC. In the U.S., KRASG12C accounts for around 37% of NSCLC cases, while KRASG12D occurs in approximately 42% of pancreatic cancer cases, 30% of CRC cases, and 42% of LGSOC cases.
• Among the approved KRAS inhibitor therapies, AVMAPKI + FAKZYNJA is anticipated to hold a larger market share than KRAZATI and LUMAKRAS during the forecast period (2020-2034).
• Key KRAS Inhibitors Companies: Pfizer, Roche/Chugai/Genentech, Revolution Medicines, Eli Lilly and Company, Merck, Taiho, and Astex Pharmaceuticals, Elicio Therapeutics, Jiangsu Hengrui Pharmaceuticals, Cardiff Oncology, Genfleet Therapeutics and Innovent, Jacobio Pharma, Tyligand Pharmaceuticals (Suzhou), Silexion Therapeutics and Catalent, Astellas Pharma, Incyte, Quanta Therapeutics, and others
• Key KRAS Inhibitors Therapies: PF-07934040, Divarasib (RG6330), Daraxonrasib (RMC-6236), Olomorasib + Pembrolizumab ± Chemotherapy, MK-1084 + Pembrolizumab:, Onvansertib + Bevacizumab + FOLFIRI/ FOLFOX, ELI-002, HRS-4642 + Gemcitabine + Albumin-bound Paclitaxel, DUPERT (Fulzerasib/GFH925) + Cetuximab, JAB-23E73, TSN1611, SIL204, ASP3082, INCB186748, QTX3544, and others
• The KRAS Inhibitors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage KRAS Inhibitors pipeline products will significantly revolutionize the KRAS Inhibitors market dynamics.

KRAS Inhibitors Overview
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of mutated KRAS proteins, which are commonly found in cancers like non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer. KRAS mutations, especially variants like G12C and G12D, drive uncontrolled cell growth. By targeting these mutations, KRAS inhibitors help slow tumor progression and improve treatment outcomes. Approved drugs such as LUMAKRAS and KRAZATI represent major advancements in treating KRAS-mutant cancers, with ongoing research exploring combination therapies and broader applications across cancer types.

Get a Free sample for the KRAS Inhibitors Market Report
https://www.delveinsight.com/report-store/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

KRAS Inhibitors Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

KRAS Inhibitors Epidemiology Segmentation:
The KRAS Inhibitors market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of KRAS Inhibitors
• Prevalent Cases of KRAS Inhibitors by severity
• Gender-specific Prevalence of KRAS Inhibitors
• Diagnosed Cases of Episodic and Chronic KRAS Inhibitors

Download the report to understand which factors are driving KRAS Inhibitors epidemiology trends @ KRAS Inhibitors Epidemiology Forecast
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

KRAS Inhibitors Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the KRAS Inhibitors market or expected to get launched during the study period. The analysis covers KRAS Inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the KRAS Inhibitors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

KRAS Inhibitors Therapies and Key Companies
• PF-07934040: Pfizer
• Divarasib (RG6330): Roche/Chugai/Genentech
• Daraxonrasib (RMC-6236): Revolution Medicines
• Olomorasib + Pembrolizumab ± Chemotherapy: Eli Lilly and Company
• MK-1084 + Pembrolizumab: Merck, Taiho, and Astex Pharmaceuticals
• Onvansertib + Bevacizumab + FOLFIRI/ FOLFOX: Cardiff Oncology
• ELI-002: Elicio Therapeutics
• HRS-4642 + Gemcitabine + Albumin-bound Paclitaxel: Jiangsu Hengrui Pharmaceuticals
• DUPERT (Fulzerasib/GFH925) + Cetuximab: Genfleet Therapeutics and Innovent
• JAB-23E73: Jacobio Pharma
• TSN1611: Tyligand Pharmaceuticals (Suzhou)
• SIL204: Silexion Therapeutics and Catalent
• ASP3082: Astellas Pharma
• INCB186748: Incyte
• QTX3544: Quanta Therapeutics

Discover more about therapies set to grab major KRAS Inhibitors market share @ KRAS Inhibitors Treatment Market
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

KRAS Inhibitors Market Drivers
• Rising prevalence of KRAS-mutated cancers: The growing burden of cancers harboring KRAS mutations, particularly colorectal, non-small cell lung, and pancreatic cancers, is creating significant demand for targeted therapies.
• Expansion of approved KRAS inhibitors: Clinical and commercial progress with KRAS-targeted therapies, particularly KRAS G12C inhibitors, is validating the therapeutic approach and supporting market growth.
• Growing pipeline of next-generation inhibitors: Development of pan-KRAS, KRAS G12D, KRAS G12V, and other mutation-specific inhibitors is expanding the addressable patient population beyond G12C.
• Strong pharmaceutical investment: Increasing partnerships, licensing agreements, acquisitions, and R&D investments are accelerating the development of KRAS-targeted therapies and combination regimens.
• Potential for combination therapies: Research combining KRAS inhibitors with immunotherapies, chemotherapy, EGFR inhibitors, and other targeted agents is creating opportunities to improve response durability and overcome resistance.

KRAS Inhibitors Market Barriers
• Acquired and intrinsic resistance: Development of secondary KRAS mutations, pathway reactivation, and alternative signaling mechanisms can reduce treatment effectiveness and limit long-term clinical benefit.
• Tumor heterogeneity: Differences in KRAS mutations and co-occurring genomic alterations across patients make treatment selection and development of broadly effective inhibitors challenging.
• Limited efficacy in some indications: Response rates and durability can vary across tumor types, particularly in heavily pretreated or advanced cancers, creating challenges for wider adoption.
• Safety and tolerability concerns: Adverse events and drug-drug interactions associated with KRAS inhibitors may affect treatment adherence and require careful patient monitoring.
• High development and treatment costs: Complex biomarker-driven clinical trials, companion diagnostic requirements,

Scope of the KRAS Inhibitors Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key KRAS Inhibitors Companies: Pfizer, Roche/Chugai/Genentech, Revolution Medicines, Eli Lilly and Company, Merck, Taiho, and Astex Pharmaceuticals, Elicio Therapeutics, Jiangsu Hengrui Pharmaceuticals, Cardiff Oncology, Genfleet Therapeutics and Innovent, Jacobio Pharma, Tyligand Pharmaceuticals (Suzhou), Silexion Therapeutics and Catalent, Astellas Pharma, Incyte, Quanta Therapeutics, and others
• Key KRAS Inhibitors Therapies: PF-07934040, Divarasib (RG6330), Daraxonrasib (RMC-6236), Olomorasib + Pembrolizumab ± Chemotherapy, MK-1084 + Pembrolizumab:, Onvansertib + Bevacizumab + FOLFIRI/ FOLFOX, ELI-002, HRS-4642 + Gemcitabine + Albumin-bound Paclitaxel, DUPERT (Fulzerasib/GFH925) + Cetuximab, JAB-23E73, TSN1611, SIL204, ASP3082, INCB186748, QTX3544, and others
• KRAS Inhibitors Therapeutic Assessment: KRAS Inhibitors current marketed and KRAS Inhibitors emerging therapies
• KRAS Inhibitors Market Dynamics: KRAS Inhibitors market drivers and KRAS Inhibitors market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• KRAS Inhibitors Unmet Needs, KOL's views, Analyst's views, KRAS Inhibitors Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.